Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study

In the global KEYNOTE‐042 study (Clinicaltrials.gov, NCT02220894), pembrolizumab significantly improved overall survival (OS) vs chemotherapy in patients with previously untreated programmed death ligand 1 (PD‐L1)‐positive locally advanced/metastatic non–small‐cell lung cancer (NSCLC) without EGFR/A...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yi‐Long, Zhang, Li, Fan, Yun, Zhou, JianYing, Zhou, Qing, Li, Wei, Hu, ChengPing, Chen, GongYan, Zhang, Xin, Zhou, CaiCun, Dang, Thao, Sadowski, Sara, Kush, Debra A., Zhou, Yu, Li, Ben, Mok, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048589/
https://www.ncbi.nlm.nih.gov/pubmed/33231285
http://dx.doi.org/10.1002/ijc.33399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048589/
https://www.ncbi.nlm.nih.gov/pubmed/33231285
http://dx.doi.org/10.1002/ijc.33399

Ejemplares similares